ReviewInnere Medizin (Heidelberg, Germany)2026
[Staphylococcus aureus bacteremia: the long road to adequate therapy : Recent studies].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStaphylococcus aureus bacteremia (SAB) is a heterogeneous and difficult-to-treat disease with a high mortality rate.
objectivesPresentation of the challenges of randomized controlled trials (RCTs) on SAB, and an overview of the current state of research and future studies.
methodsSearch for RCTs on SAB in PubMed and clinicaltrials.gov over the past 20 years.
resultsThe design and implementation of RCTs on SAB is complex. Current RCTs incorporate new developments such as pragmatic study design, adaptive platform studies, endpoints with a desirability of outcome ranking (DOOR) and enrichment of clinical phenotypes. The latest results regarding therapy show that cefazolin is not inferior to flucloxacillin in the treatment of methicillin-susceptible S. aureus (MSSA)-SAB and is less nephrotoxic. There is no general recommendation for combination therapy. In low-risk SAB, early oral switch therapy is possible after 5-7 days.
conclusionsRCTs on SAB therapy require careful planning and inclusion of subgroups. Further RCTs are necessary to optimize therapy.
Indexed as
Identifiers
41405603What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.